Overview
FOR PHYSICIAN CREDIT: From Provider To Patient: Opportunities and Dialogue for Appropriate Pain Management
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This activity educates physicians, pharmacists, and other allied health personnel on the latest CDC guidelines surrounding prescription opioids as well as the latest epidemiological data surrounding addiction management and treatment. Multiple expert physicians trained in pain management as well as addiction management will discuss current best practices in both disciplines, while academic pharmacists will explain mechanisms of action, potential side effects, and regulatory issues surrounding prescription opioid medications, including novel therapies that employ abuse-deterrent technology.
This activity is designed for clinicians involved in the care and treatment of patients with chronic pain, as well as pain patients who may be at risk for substance abuse.
Nearly 100 million people in the United States, or roughly one-third of the population, experience some form of chronic pain. Meanwhile, prescription opiate abuse and addiction have reached epidemic proportions in the United States, including the widespread illegal diversion of prescription opioids for street use, which in turn can increase the rates of abuse of illegal narcotics. Some clinicians have also prescribed opioids without adequate training surrounding their abuse potential. Many primary care providers have recently become reluctant to prescribe opioid pain relievers in the context of current public health concerns surrounding addiction, which leads to some chronic pain patients now going without any appropriate treatment. The development of new clinical practice guidelines from the Centers for Disease Control and Prevention (CDC) regarding prescription opioids presents both a challenge and an opportunity for clinicians to offer safer and more effective management of pain. Meanwhile, the development of new opioid therapeutic options that employ abuse-deterrent technology may help reduce the illegal diversion of prescription opiates for street use.
Upon completion of this educational activity, learners should be able to:
• Illustrate the components that should be assessed and documented for CNCP during an initial and subsequent patient visits.
• Describe how the 2016 guideline updates impact opioid prescribing, monitoring, and patient access and how they may be implemented practically and for the benefit of the patient.
• Review the different types of formulations and how they serve as abuse deterrents in patients on chronic opioid therapy.
• Diagram components of a collaborative care approach in order to improve outcomes of patients receiving COT
This activity is sponsored by the Academy for Continued Healthcare Learning.
This activity is supported by educational funding provided by Teva Pharmaceuticals.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Ruixuan Jiang, PharmD
PhD Student
University of Illinois at Chicago
College of Pharmacy
Department of Pharmacy Systems, Outcomes, and Policy
Chicago, IL
PhD Student
University of Illinois at Chicago
College of Pharmacy
Department of Pharmacy Systems, Outcomes, and Policy
Chicago, IL
Todd Lee, PharmD, PhD
Professor
University of Illinois at Chicago
College of Pharmacy
Department of Pharmacy Systems, Outcomes, and Policy
Chicago, IL
Michael Phillip Sprintz, DO
Founder and CEO
Sprintz Center for Pain and Dependency
The Woodlands, TX
Forest Tennant, MD, MPH, DrPH
Pain Management Specialist
West Covina, CA
Moderated by:
Barbara Lewis, BA
Healthcare News Reporter and Anchor
Inside Indiana Business
Sound Medicine, WFYI Public Radio/Indiana University School of Medicine
Moderated by:
Barbara Lewis, BA
Healthcare News Reporter and Anchor
Inside Indiana Business
Sound Medicine, WFYI Public Radio/Indiana University School of Medicine
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:
Ruixuan Jiang, PharmD
Nothing to disclose
Todd Lee, PharmD, PhD
Nothing to disclose
Michael Phillip Sprintz, DO
Cellarian Health, LLC: CEO
Daichii Sankyo, Inc.: Consultant
Endo Pharmaceuticals: Chronic Pain Advisory Board – honorarium recipient/consultant
Forest Tennant, MD, MPH, DrPH
Nothing to disclose
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take 60 minutes to complete. To obtain credit, a score of 60% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, completed the post-test and evaluation, and have received a digital copy of your credit certificate.
The Academy for Continued Healthcare Learning (ACHL) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.